← Browse by Condition
Medical Condition

myelodysplastic syndromes

Total Trials
18
Recruiting Now
18
Trial Phases
Phase 1, Phase 2, Phase 2, Phase 1

ClinicalMetric tracks all active clinical trials for myelodysplastic syndromes sourced from ClinicalTrials.gov. Research in this area spans early-phase safety investigations through large Phase 3 confirmatory trials, conducted by NIH-funded academic centers, independent investigators, and pharmaceutical sponsors worldwide. Each listing is updated daily as new studies open enrollment and existing ones reach capacity or complete follow-up.

Trial listings include the NCT identifier, current recruitment status, phase classification, primary and secondary endpoints, estimated enrollment size, participating countries, and direct links to the full protocol on ClinicalTrials.gov. Eligibility criteria — including age range, disease stage, and prior treatment requirements — are documented for every study to help patients and clinicians assess suitability before contacting a trial site.

Frequently Asked Questions — myelodysplastic syndromes Clinical Trials

How many clinical trials are currently recruiting for myelodysplastic syndromes?
ClinicalMetric currently tracks 18 actively recruiting clinical trials for myelodysplastic syndromes, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 18. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.
What trial phases are available for myelodysplastic syndromes?
myelodysplastic syndromes research spans Phase 1 (8 trials), Phase 2 (10 trials). Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.
How do I find out if I qualify for a myelodysplastic syndromes clinical trial?
Eligibility criteria for myelodysplastic syndromes trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.
Trial Phases
Phase 1
8
Phase 2
10
Top Sponsors
UNC Lineberger Comprehensive Cancer Center 1 trial
Chordia Therapeutics, Inc. 1 trial
BeOne Medicines 1 trial
Groupe Francophone des Myelodysplasies 1 trial
Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico 1 trial

Recruiting Clinical Trials

NCT01137825
Recruiting
Registry of Older Patients With Cancer
Enrollment
3,000 pts
Location
United States
Sponsor
UNC Lineberger Comprehensive C...
View Trial →
NCT05732103 Phase 1, Phase 2
Recruiting
A Study of CTX-712 in Relapsed/Refractory Acute Myeloid Leukemia and Higher Risk Myelodysplastic Syndromes
Enrollment
225 pts
Location
United States
Sponsor
Chordia Therapeutics, Inc.
View Trial →
NCT04771130 Phase 1, Phase 2
Recruiting
A Study of BGB-11417 in Participants With Myeloid Malignancies
Enrollment
260 pts
Location
United States, Austr...
Sponsor
BeOne Medicines
View Trial →
NCT06956755
Recruiting
Registry of Myelodysplastic Syndromes and Therapy-related Acute Myeloid Leukemia
Enrollment
6,990 pts
Location
France
Sponsor
Groupe Francophone des Myelody...
View Trial →
NCT05931718
Recruiting
Prospective Evaluation of Diagnosis and Treatment of Patients With Autoimmune Cytopenias Including Autoimmune Hemolytic Anemia, Immune Thrombocytopenia, and Chronic Idiopathic/Autoimmune Neutropenia
Enrollment
200 pts
Location
Italy
Sponsor
Fondazione IRCCS Ca' Granda, O...
View Trial →
NCT05384691 Phase 2
Recruiting
Efficacy of Luspatercept in ESA-naive LR-MDS Patients With or Without Ring Sideroblasts Who do Not Require Transfusions
Enrollment
213 pts
Location
Germany
Sponsor
University of Leipzig
View Trial →
NCT07302776 Phase 1
Recruiting
TACrolimus Targeted Immunosuppression Cessation in ALlogeneic HCT
Enrollment
50 pts
Location
United States
Sponsor
Stanford University
View Trial →
NCT07183878
Recruiting
Venetoclax-Enhanced BUCY vs. Standard BUCY Conditioning in High-Risk AML and MDS Patients Undergoing Allo-HSCT (Ven-BUCY Study)
Enrollment
138 pts
Location
China
Sponsor
First Affiliated Hospital of Z...
View Trial →
NCT05788679 Phase 2
Recruiting
A Study Using Subject-specific MRD to Adopt Treatment After HSCT for Subjects With MDS
Enrollment
200 pts
Location
Sweden
Sponsor
Karolinska University Hospital
View Trial →
NCT01890486
Recruiting
The Prospective Collection, Storage and Reporting of Data on Patients Undergoing Hematopoietic Stem Cell Transplantation Utilizing a Standard Preparative Regimen
Enrollment
2,000 pts
Location
United States
Sponsor
Wake Forest University Health ...
View Trial →
NCT05636514 Phase 1
Recruiting
Combined Evaluation of Epigenetic and Sensitising Therapy in AML and MDS
Enrollment
12 pts
Location
Australia
Sponsor
Clinical Hub for Interventiona...
View Trial →
NCT03999723 Phase 2
Recruiting
Combining Active and Passive DNA Hypomethylation
Enrollment
196 pts
Location
Denmark, Sweden
Sponsor
Kirsten Grønbæk
View Trial →
NCT06315309 Phase 2
Recruiting
Trial of 2 Step ATG for Acute GVHD Prevention Post Myeloablative Allogeneic Stem Cell Transplant
Enrollment
29 pts
Location
United States
Sponsor
University of Alabama at Birmi...
View Trial →
NCT04742634 Phase 1, Phase 2
Recruiting
Pre-emptive Therapy With DEC-C to Improve Outcomes in MDS Patients With Measurable Residual Disease Post Allogeneic Hematopoietic Cell Transplant
Enrollment
209 pts
Location
United States
Sponsor
Washington University School o...
View Trial →
NCT04245397 Phase 1
Recruiting
Study of SX-682 Alone and in Combination With Oral or Intravenous Decitabine in Subjects With Myelodysplastic Syndrome
Enrollment
151 pts
Location
United States
Sponsor
Syntrix Biosystems, Inc.
View Trial →
NCT07677306 Phase 2
Recruiting
Age-Stratified Conditioning Regimen Efficacy for MDS Haplo-HSCT
Enrollment
120 pts
Location
China
Sponsor
Peking University People's Hos...
View Trial →
NCT03886662 Phase 1, Phase 2
Recruiting
A Study of LB-100 in Patients With Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS)
Enrollment
47 pts
Location
United States
Sponsor
Lixte Biotechnology Holdings, ...
View Trial →
NCT03300492 Phase 1, Phase 2
Recruiting
Expanded Natural Killer Cells Following Haploidentical HSCT for AML/MDS
Enrollment
10 pts
Location
Switzerland
Sponsor
University Hospital, Basel, Sw...
View Trial →

Related Conditions

acute myeloid leukemia (6) chronic myelomonocytic leukemia (2) chronic myeloproliferative disorders (1) cognitive functional effects (1) leukemia (1) lymphoma (1) lymphoproliferative disorder (1) multiple myeloma and plasma cell neoplasm (1) myelodysplastic myeloproliferative neoplasms (1) unspecified adult solid tumor protocol specific (1) myelodysplastic myeloproliferative neoplasm (1) leukemia myeloid acute (1)
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: November 2026  ·  Data Methodology